PDUFA dates September 2024: FDA calendar and catalysts.
2 PDUFA dates fell in September 2024: NEREUSTM (September 18), RPRX (September 26). The FDA calendar also recorded 63 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
PDUFA dates in September 2024
| PDUFA date | Company | Ticker | Drug | Indication | Source |
|---|---|---|---|---|---|
| September 18, 2024 | Vanda Pharmaceuticals Inc. | VNDA | NEREUSTM (tradipitant) | symptoms of gastroparesis to a final decision prior | SEC Form 10-Q, filed 2025-10-30 |
| September 26, 2024 | Royalty Pharma plc | RPRX | Not named | schizophrenia in adults | SEC Form 10-K, filed 2025-02-12 |
Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months
September 2024: other FDA decisions and filings
September 2024: dated readouts
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| Sep 2024Month disclosed | Juvmo (tavapadon) | ABBV | Topline readout | — | Positive | SEC Form 10-K |
| Sep 2024Month disclosed | VYGLXIA (troriluzole) | BHVN | Topline readout | — | Positive | SEC 8-K Exhibit 99.1 |
| Sep 2024Month disclosed | SPINRAZA (nusinersen) | BIIB | Topline readout | — | Positive | SEC Form 10-K |
| Sep 2024Month disclosed | dapirolizumab pegol | BIIB | Topline readout | moderate-to-severe SLE | Positive | SEC Form 10-K |
| Sep 2024Month disclosed | extension (SPY004) | DYN | Topline readout | — | Positive | SEC Form 10-K |
| Sep 2024Month disclosed | EDP-323 | ENTA | Topline readout | — | Positive | SEC 8-K Exhibit 99.1 |
| Sep 2024Month disclosed | losmapimod | FULC | Topline readout | — | Mixed | SEC Form 10-Q |
| Sep 2024Month disclosed | fosgonimeton | LONA | Topline readout | — | Missed primary endpoint | SEC Form 10-Q |
| Sep 2024Month disclosed | DA-1726 | MTVA | Topline readout | obesity | Positive | sec_424b |
| Sep 2024Month disclosed | VAX-31 | PCVX | Topline readout | — | Positive | SEC Form 10-Q |
| Sep 2024Month disclosed | superoxide (REC-994) | RXRX | Topline readout | — | Met primary endpoint | SEC Form 10-K |
| Sep 2024Month disclosed | — | VRDN | Topline readout | — | Positive | SEC Form 10-K |
| September 6, 2024 | JX02002 | MIST | Topline readout | PSVT in China | Positive | SEC Form 10-Q |
| September 19, 2024 | EDG-7500 | EWTX | Topline readout | oHCM | Positive | sec_424b |
September 2024: trial starts and primary completions
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| Sep 2024Month disclosed | IGALMI® (dexmedetomidine) | BTAIQ | Trial start | — | Completed | SEC Form 8-K |
| September 25, 2024 | CRS3123 | ACXP | Trial start | — | Completed | SEC Form 10-K |
| Sep 2024Month disclosed | BH-2100 | BHVN | Trial start | — | Completed | SEC Form 10-Q |
| Sep 2024Month disclosed | BHV-2100 | BHVN | Trial start | — | Completed | SEC 8-K Exhibit 99.1 |
| Sep 2024Month disclosed | INDV-6001 | SUPN | Trial start | — | Completed | SEC Form 10-K |
| Sep 2024Month disclosed | arrows (MC138) | RNAZ | Trial start | — | Completed | SEC Form 10-Q |
| Sep 2024Month disclosed | REC-1245 | RXRX | Trial start | — | Completed | SEC Form 10-K |
| Sep 2024Month disclosed | aritinercept (AUR200) | AUPH | Trial start | — | Completed | SEC 8-K Exhibit 99.1 |
| Sep 2024Month disclosed | CLN-619 | CGEM | Trial start | relapsed/refractory multiple myeloma | Completed | SEC Form 10-K |
| Sep 2024Month disclosed | CDI-988 | COCP | Trial start | — | Completed | sec_s1 |
| Sep 2024Month disclosed | MZE782 | MAZE | Trial start | — | Completed | sec_424b |
| September 30, 2024 | CUE-101 | CUE | Trial start | — | Completed | SEC Form 10-Q |
25 more milestones are guided to a half-year or full-year window, or estimated from ClinicalTrials.gov primary completion dates, that overlaps September 2024. They are on each drug page and in the calendar API.
Questions
What PDUFA dates are in September 2024?
2 PDUFA dates fell in September 2024: NEREUSTM (September 18), RPRX (September 26). The FDA calendar also recorded 63 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
Can these dates change?
Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.